Antimicrobial resistance profiles of Escherichia coli isolated from clinical and environmental samples: findings and implications.

IF 3.7 Q2 INFECTIOUS DISEASES
JAC-Antimicrobial Resistance Pub Date : 2024-04-27 eCollection Date: 2024-04-01 DOI:10.1093/jacamr/dlae061
Maisa Kasanga, Doreen Mainza Shempela, Victor Daka, Mark J Mwikisa, Jay Sikalima, Duncan Chanda, Steward Mudenda
{"title":"Antimicrobial resistance profiles of <i>Escherichia coli</i> isolated from clinical and environmental samples: findings and implications.","authors":"Maisa Kasanga, Doreen Mainza Shempela, Victor Daka, Mark J Mwikisa, Jay Sikalima, Duncan Chanda, Steward Mudenda","doi":"10.1093/jacamr/dlae061","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The overuse and misuse of antimicrobials has worsened the problem of antimicrobial resistance (AMR) globally. This study investigated the AMR profiles of <i>Escherichia coli</i> isolated from clinical and environmental samples in Lusaka, Zambia.</p><p><strong>Methods: </strong>This was a cross-sectional study conducted from February 2023 to June 2023 using 450 samples. VITEK<sup>®</sup> 2 Compact was used to identify <i>E. coli</i> and perform antimicrobial susceptibility testing. Data analysis was done using WHONET 2022 and SPSS version 25.0.</p><p><strong>Results: </strong>Of the 450 samples, 66.7% (<i>n</i> = 300) were clinical samples, whereas 33.3% (<i>n</i> = 150) were environmental samples. Overall, 47.8% (<i>n</i> = 215) (37.8% clinical and 10% environmental) tested positive for <i>E. coli</i>. Of the 215 <i>E. coli</i> isolates, 66.5% were MDR and 42.8% were ESBL-producers. Most isolates were resistant to ampicillin (81.4%), sulfamethoxazole/trimethoprim (70.7%), ciprofloxacin (67.9%), levofloxacin (64.6%), ceftriaxone (62.3%) and cefuroxime (62%). Intriguingly, <i>E. coli</i> isolates were highly susceptible to amikacin (100%), imipenem (99.5%), nitrofurantoin (89.3%), ceftolozane/tazobactam (82%) and gentamicin (72.1%).</p><p><strong>Conclusions: </strong>This study found a high resistance of <i>E. coli</i> to some antibiotics that are commonly used in humans. The isolation of MDR and ESBL-producing <i>E. coli</i> is a public health concern and requires urgent action. Therefore, there is a need to instigate and strengthen interventional strategies including antimicrobial stewardship programmes to combat AMR in Zambia.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11055401/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The overuse and misuse of antimicrobials has worsened the problem of antimicrobial resistance (AMR) globally. This study investigated the AMR profiles of Escherichia coli isolated from clinical and environmental samples in Lusaka, Zambia.

Methods: This was a cross-sectional study conducted from February 2023 to June 2023 using 450 samples. VITEK® 2 Compact was used to identify E. coli and perform antimicrobial susceptibility testing. Data analysis was done using WHONET 2022 and SPSS version 25.0.

Results: Of the 450 samples, 66.7% (n = 300) were clinical samples, whereas 33.3% (n = 150) were environmental samples. Overall, 47.8% (n = 215) (37.8% clinical and 10% environmental) tested positive for E. coli. Of the 215 E. coli isolates, 66.5% were MDR and 42.8% were ESBL-producers. Most isolates were resistant to ampicillin (81.4%), sulfamethoxazole/trimethoprim (70.7%), ciprofloxacin (67.9%), levofloxacin (64.6%), ceftriaxone (62.3%) and cefuroxime (62%). Intriguingly, E. coli isolates were highly susceptible to amikacin (100%), imipenem (99.5%), nitrofurantoin (89.3%), ceftolozane/tazobactam (82%) and gentamicin (72.1%).

Conclusions: This study found a high resistance of E. coli to some antibiotics that are commonly used in humans. The isolation of MDR and ESBL-producing E. coli is a public health concern and requires urgent action. Therefore, there is a need to instigate and strengthen interventional strategies including antimicrobial stewardship programmes to combat AMR in Zambia.

从临床和环境样本中分离的大肠埃希菌的抗菌药耐药性概况:研究结果和意义。
背景:抗菌药的过度使用和滥用使全球抗菌药耐药性(AMR)问题日益严重。本研究调查了从赞比亚卢萨卡的临床和环境样本中分离出的大肠埃希菌的耐药性概况:这是一项横断面研究,研究时间为 2023 年 2 月至 2023 年 6 月,使用了 450 份样本。使用 VITEK® 2 Compact 鉴定大肠杆菌并进行抗菌药敏感性测试。数据分析采用 WHONET 2022 和 SPSS 25.0 版:在 450 份样本中,66.7%(n = 300)为临床样本,33.3%(n = 150)为环境样本。总体而言,47.8%(n = 215)(37.8%为临床样本,10%为环境样本)的大肠杆菌检测结果呈阳性。在 215 个大肠杆菌分离物中,66.5% 为 MDR,42.8% 为 ESBL 产物。大多数分离株对氨苄西林(81.4%)、磺胺甲恶唑/三甲氧苄(70.7%)、环丙沙星(67.9%)、左氧氟沙星(64.6%)、头孢曲松(62.3%)和头孢呋辛(62%)产生耐药性。令人费解的是,大肠杆菌分离株对阿米卡星(100%)、亚胺培南(99.5%)、硝基呋喃妥因(89.3%)、头孢唑烷/他唑巴坦(82%)和庆大霉素(72.1%)高度敏感:本研究发现,大肠杆菌对人类常用的一些抗生素具有高度耐药性。分离出产生 MDR 和 ESBL 的大肠杆菌是一个公共卫生问题,需要采取紧急行动。因此,有必要制定并加强包括抗菌药物管理计划在内的干预策略,以应对赞比亚的AMR问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信